Abstract | After 60 years of intense fundamental research into T cell-mediated cytotoxicity , we have gained a detailed knowledge of the cells involved, specific recognition mechanisms and post-recognition perforin-granzyme-based and FAS-based molecular mechanisms. What could not be anticipated at the outset was how discovery of the mechanisms regulating the activation and function of cytotoxic T cells would lead to new developments in cancer immunotherapy. Given the profound recent interest in therapeutic manipulation of cytotoxic T cell responses, it is an opportune time to look back on the early history of the field. This Timeline describes how the early findings occurred and eventually led to current therapeutic applications.
Initially, scientists investigated cell-mediated cytotoxicity in their efforts to understand graft rejection. They also wondered why a cytotoxicity mechanism should have been evolutionarily selected in multicellular organisms, in which cytotoxic cells could kill only other cells of the same organism. This seemed to negate the fact that multicellularity depends on cooperation between cells. We now understand that cytotoxicity defends against those syngeneic cells -that are either modified by oncogenesis or bear intracellular infectious agents that are not otherwise reachable -whose death would benefit the whole multicellular organism. The same mechanisms are also thought to be involved in artificial conditions such as allograft rejection or in pathological circumstances such as in some autoimmune diseases.
This Timeline covers 60 years of fundamental research into T cell-mediated cytotoxicity, starting with early in vitro demonstrations of cell-mediated cytotoxicity, the quantification thereof and its attribution to T cells. This was followed by more analytical investigations, by which recognition of target cells was shown to involve specific T cell surface receptors and post-recognition cytotoxicity was shown to be due to either a mechanism based on perforin and granzyme or a mechanism Early demonstrations of cytotoxicity. The first reports, in the 1960s, to show specific cytotoxicity in vitro used mostly allogeneic combinations of cells. Thus, lymphocytes from dogs bearing a kidney homograft produced specific lesions in donor kidney cultures, as visualized microscopically 1 . Similarly, lymphocytes from BALB/c mice alloimmunized with cells from C3H mice were shown to cluster on target cells of C3H origin and to induce their cytolysis. These target cells withdrew their processes and rounded up, with evidence of chromatin clumping that is suggestive, in retrospect, of apoptotic cell death 2 . Also, lymph node or thoracic duct lymphoid cells from allosensitized rodents were able to cluster around and destroy donor kidney cells in culture 4 . Cytotoxicity mediated by alloimmune mouse lymphoid cells could also be demonstrated by clonogenic assays 5 and through the inhibition of antibody plaque formation 6 . Mouse alloimmune peritoneal cells -collected 10 days after an intraperitoneal injection of allogeneic tumour cells -comprising 3-5% lymphocytes showed strong immediate allospecific adherence and cytotoxicity to fibroblast monolayers, as demonstrated by the formation of clear plaques 7 . Cytotoxicity mediated by mouse alloimmune lymph node cells could be partially blocked by alloantibodies 8 . In a xenogeneic combination, lymphoid cells from mice immunized with human HeLa cells were cytotoxic to monolayers of HeLa cells 9 . Most likely distinct from the above mechanisms, some target cells, such as L cells or embryonic fibroblasts, were shown to be sensitive to toxic substances (later defined as tumour necrosis factor or lymphotoxin) released by activated lymphocytes in an antigen-independent manner 10, 11 . Other experiments were designed to mimic syngeneic autoimmune reactions, initially using interspecies immunization. Thus, lymph node cells from Lewis rats immunized with a suspension of guinea pig spinal cord were added to dog brain cells in vitro. These sensitized rat cells (but not non-sensitized cells) agglutinated around dog glial cells (but not dog fibroblasts) and destroyed them, thus demonstrating based on FAS (also known as TNFRSF6, APO1 or CD95) (Fig. 1) . Importantly, currently emerging therapeutic applications of T cell-mediated cytotoxicity, such as cancer immunotherapy, may benefit from a consideration of its mechanistic bases.
Although natural killer (NK) cells and some CD4 + T cells are also endowed with cytotoxic activity, here we mainly discuss cytotoxicity mediated by classical cytotoxic CD8 + T cells (also known as cytotoxic T lymphocytes (CTLs)), as they have been studied most often in vitro. We focus on what we consider retrospectively to be the major advances in the field and apologize for the omission of many other excellent studies out of the several tens of thousands that have been published on this topic.
Recognizing cytotoxicity: 1960s
Pioneering experiments in the 1950s that aimed to find a mechanistic explanation for graft rejection assessed, mostly by microscopy, the cytolysis of donor tissue by sensitized lymphoid tissue in vitro. However, these experiments showed no evidence of cytotoxicity, perhaps because they were often carried out on donor explants rather than on isolated cells and also because they often aimed to show the participation of circulating antibodies and/or complement in these reactions (reviewed in reFs tissue-specific cytolysis in vitro 12 . Somewhat similarly, white blood cells or thoracic duct lymphocytes from rabbits or rats immunized with pig spinal cord agglutinated around and ultimately destroyed rat glial cells 13 .
Quantifying cytotoxicity. By the mid-1960s, it was clear, at least qualitatively, that sensitized lymphoid cells could lyse target cells in vitro. Further studies on the mechanisms of this cell-mediated cytotoxicity required better quantification. At about this time, several publications noted that the release from target cells of pre-incorporated radioisotopes, such as 32 P-containing orthophosphate or 14 C-containing amino acids, could be used as an indicator of cell damage 14, 15 . Most subsequent cytotoxicity experiments were carried out using the 51 Cr release assay. For nucleated target cells, this method was first used to evaluate the effect of antibodies in the presence of complement [16] [17] [18] and was subsequently applied to cell-mediated cytotoxicity 19, 20 . This method for assessing cytotoxicity had the advantages of being objective, short term, accurate (early users were surprised by the low dispersal of experimental triplicates) and, because of the 51 Cr half-life of 27 days and convenient gamma emission, more user-friendly than the use of other radioisotopes such as 3 H or 32 
P. The 51
Cr release assay was extensively used until the mid-1990s and is now being progressively replaced, particularly for safety reasons, by non-radioactive methods. These include the release from dying target cells of lactate dehydrogenase (LDH), calcein or cytokeratin, the uptake by dying target cells of propidium iodide or similar normally cell-impermeant dyes, the intracellular or cell-surface labelling of dying cells for activated caspases or exposed phosphatidylserine [21] [22] [23] and more sophisticated microscopy methods (see below).
identifying CTls: 1970s By the end of the 1960s, the accumulation of functional results on lymphoid cell-mediated cytotoxicity (reviewed in reF.
24
) and the emergence of appropriate methods to quantify such cytotoxicity enabled further analysis of the cells involved and their recognition mechanisms.
T cells are required for anti-allogeneic cytotoxicity. Researchers were keen to discover which cells were able to exert cytotoxicity in alloimmune spleen or lymph node cell populations. This was first [84] [85] [86] [87] [88] [89] [90] Cloning of CTLA4 (REF. 164 ) Cloning of PD1 (REF. 165 ) Perforin and granzymes shown to cooperate for cytotoxicity 96-98 (1970-1975) T cells shown to be necessary and sufficient for cytotoxicity by sensitized lymphoid cells 25-33 (1974-1983) Phenomenological dissection of T cell-mediated cytotoxicity 57, 58, [60] [61] [62] [63] [64] [65] (1964-1973) Discovery of antigen-specific receptors at the surface of CTLs 28, [41] [42] [43] 45, 46 Low levels of cytotoxicity shown for CTLs from perforin-knockout mice 80, 81 Both the FAS pathway and the perforin-granzyme pathway shown to account for T cell-mediated cytotoxicity 118-121 (1995-1996) 138, 139 (1999-2007) FASL in vesicles shown to be packaged in secretory lysosomes [146] [147] [148] (2002-2004) Antibodies against the PD1-PDL1 pathway shown to lead to tumour regression in mice 176, 177 (2008-2017) Granzymes shown to have multiple effects in target cells [99] [100] [101] [102] [103] 144 (1964-1968) Development of the 51 Cr release assay for nucleated target cells 17-20 (1972-1974) Studies of the MHC restriction of recognition by T cells [37] [38] [39] [40] (1999-2010) HLH shown to be due to mutations in perforin or in secretion-required molecules 131, 132 Remissions observed in a minority of patients with melanoma who were treated with antibodies against CTLA4 (REF. investigated by treating such populations with T cell-specific antisera and then testing their residual cytotoxicity. In the presence of complement, but usually not in its absence, antisera such as anti-Thy1 (reFs [25] [26] [27] ) (Thy1 later being known as CD90), heterologous anti-T 28 and most notably anti-Ly23 (reF.
29
) (Ly23 later being known as CD8) largely abolished subsequent anti-allogeneic cytotoxicity of mouse cells. This showed that such cytotoxicity requires T cells.
T cells are sufficient for anti-allogeneic cytotoxicity. The demonstration that T cells are not only required but also sufficient for cytotoxicity was provided by using T cell-rich populations, such as thymus cells, that were allosensitized either in vivo or in vitro and then subjected to various methods for the depletion of non-T cells before testing for cytotoxicity 25, 27, 28, [30] [31] [32] [33] . A main conclusion from these studies was that a very small number of highly purified T cells was still able to exert cytotoxicity 27 , which makes it unlikely that non-T cells take part in the effector phase of T cell-mediated cytotoxicity. This autonomy of CTLs at the effector stage was consistent with the visualization of cell conjugates that often contained only one effector cell killing one target cell (see below).
Early attempts to demonstrate specific surface receptors. Thus, by the early 1970s, it was clear that some T cells can autonomously induce target cell death. Analytical methods were then required to begin to dissect the mechanisms of this cytotoxicity. A good starting point was the hypothesis, discussed by D. Bernard Amos in the conclusion of an extensive review in 1962 (reF.
3
), that the specificity of cytotoxicity is the result of a specific recognition step (for example, through Paul Ehrlich's so-called sessile antibodies on the cell surface) followed by nonspecific cytotoxicity rather than the result of specificity of the cytotoxic mechanism per se. Thus, specific recognition of target cells by CTLs putatively implied the existence of specific T cell surface receptors, which was also relevant to the then ongoing search for the T cell receptor for antigen 34 .
Of note, columns of antigen-coated beads retained antigen-specific B cells, thus demonstrating the existence of specific receptors for antigen at the B cell surface 35 , but could not retain antigen-specific T cells 36 . It was then realized that the recognition of antigen by T cells requires the presentation of this antigen through MHC molecules at the cell surface [37] [38] [39] [40] ; this was an important finding by itself and one of the key discoveries in T cell biology, and it also explained why antigen-coated beads failed to specifically retain antigen-specific CTLs, whereas cell monolayer techniques (detailed below) succeeded. 41 , were incubated on macrophage monolayers, and the non-adherent cells were then tested for specific cytotoxic activity. Cytotoxic activity of non-adherent cells was lost if incubation had been on monolayers bearing the immunizing H2 alloantigens, which strongly suggested that the cytotoxic cells were adsorbed on these monolayers because they bore surface receptors recognizing these antigens 42 . These studies also included investigations of the precise specificity of H2 congenic alloreactions and their implications regarding the existence, nature and specificity of T cell receptors 42, 43 (reviewed in reF.
44
). One cannot help but be impressed by the published work of Brondz in terms of the quality of his experiments and discussion, in particular in light of the few contacts with Western scientists that were available at that time.
The specific loss of cytotoxic activity by adsorption of alloimmune mouse lymphocytes on relevant cell monolayers could be reproduced in a more convenient and quantitative manner soon afterwards using fibroblast monolayers and a 51 Cr release assay 45, 46 , also making use of highly purified T cells 28 . Moreover, after the incubation of alloimmune lymphocytes on relevant fibroblast monolayers, not only did non-adsorbed lymphocytes lose cytotoxicity but adsorbed lymphocytes also could be recovered from the adsorbing monolayers and shown to be cytotoxic. This showed that the loss of cytotoxic activity of adherent cells was due to specific cell adsorption rather than specific inactivation 45, 46 . The existence of specific receptors for alloantigens was similarly demonstrated on normal mouse lymphocytes before sensitization 47 . Together, these experiments showed the existence of specific receptors for antigen at the surface of CTLs and their precursors.
Specific CTL-target cell conjugates.
Conjugates formed between one effector cell and one target cell could be obtained 48 using tumour target cells and cytotoxic alloimmune lymphocytes from peritoneal exudate 49 . Study of these conjugates confirmed that a single CTL was required and sufficient to kill a target cell and that a CTL could recycle, which showed that effector cells do not die when killing target cells 48 . By microcinematography, sensitized lymphocytes were seen to approach the target cell, form a conjugate and then leave the target cell. The target cell burst after a delay, whereas the cell that had killed it was able to approach and kill other target cells 50, 51 . Electron microscopy also showed
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Cr release assay An assay that evaluates the percentage of target cells that are lysed by cytotoxic T cells by measuring the proportion of radioactivity released from pre-labelled target cells.
Allogeneic
A term that describes tissues or cells that are of the same species but are not genetically identical.
Antibody plaque formation
The ability of haemolytic antibody-forming lymphocytes to form plaques of lysed red blood cells in agar after being subjected to, for example, cytotoxic T cells.
Clonogenic assays
Assays used to determine the percentage of cells that are able to form colonies in vitro after being subjected to, for example, cytotoxic T cells.
Congenic
A term that describes tissues or cells that genetically differ by only one chromosomal region.
Haemophagocytic lymphohistiocytosis (HLH).
A human autosomal recessive disorder that results from mutation of one of five genes, including the gene encoding perforin, and that leads to T cell hyperproliferation.
Homograft
A graft from a donor of the same species as the recipient.
lpr mice
Mice bearing the lpr mutation of the Fas gene, which leads to a lymphoproliferative phenotype.
Syngeneic
A term that describes tissues or cells that are genetically identical.
Xenogeneic
A term that describes tissues or cells that are of different species.
the close apposition of effector and target cell membranes during conjugate formation 51 .
Linking killing and dying. A striking observation made by Colin Sanderson using microcinematography was that, after being exposed to CTLs, dying target cells showed cell surface blebbing, which was distinct from the events that occur during complement-mediated lysis 52 and similar to the apoptotic cell death that had recently been described in detail 53 . Importantly, this suggested that CTLs did not kill the target cells directly but signalled to them to undergo cell death using their own self-destruction machinery 52 . Also, if -as discussed above and in line with earlier results -the specific recognition of target cells and cell death signalling were separate steps, then these studies suggested that the post-recognition death signals need not be antigen specific. However, the death signals would need to somehow be polarized towards the target cells, as CTLs were not killed when killing target cells despite being sensitive to killing by other CTLs 54 . These and additional more detailed phenomenological advances obtained through diverse analytical methods 55, 56 were abundantly reviewed at the time [57] [58] [59] [60] [61] [62] [63] [64] [65] . An important development during this period was the ability to clone CTLs [66] [67] [68] . These advances set the stage in the early 1980s for researchers to begin to determine the post-recognition mechanism(s) that are involved in target cell killing (Fig. 2 ).
Cytotoxic mechanisms: 1980s to 1990s
The identification of post-recognition mechanisms was made possible, in particular, by the emergence in the field of molecular biology approaches, such as transfection, subtractive cDNA cloning and gene inactivation.
The perforin-granzyme pathway.
Microscopic observations provided a first hint as to the possible nature of a post-recognition mechanism of cytotoxicity. Tubular lesions were observed in target cell membranes after incubation with cytotoxic cells 69, 70 and also after incubation with purified granules from various types of cytotoxic cells [71] [72] [73] . A cytolytic protein known as perforin could be isolated from these granules [74] [75] [76] [77] and was found to be homologous to the ninth component of complement 78 . These important findings were in line with a granule exocytosis model of cytotoxicity proposed by Pierre Henkart, who hypothesized that "target cell binding to a membrane receptor induces a secretory process in the effector cell in which the contents of cytoplasmic granules are released by local exocytosis between the effector cell and its bound target" (reF.
75
). Such a model implied that effector cell granules containing perforin (together with other required molecules, as shown later) were delivered to the target cell. The involvement of perforin in a major mechanism of cytotoxicity was confirmed a few years later by studies showing the marked decrease in cytotoxicity mediated by CTLs transfected with perforin antisense material 79 or CTLs from perforin-knockout mice 80, 81 . However, CTLs had been shown previously to induce apoptosis, whereas purified perforin induced a different type of cell death similar to necrosis. This suggested at the time that perforin could not be the only effector molecule of target cell death and that it had to function in association with other molecules to induce apoptosis. . Alternatively , other studies have suggested that FASL is contained in distinct granules from perforin and granzymes 194 . Granules within the CTL open into the intercellular cleft (the immunological synapse) upon CTL activation, where they release their contents. This can lead to two distinct mechanisms of cell death in the target cell. In one mechanism, FASL engages FAS at the target cell membrane, leading, through FAS-associated death domain protein (FADD), to the activation of caspase 8. This in turn leads to the cleavage and thus activation of caspase 3 and subsequent apoptosis. In the other mechanism, perforin opens a channel in the target cell membrane through which granzyme B enters the cytosol and activates caspase 3, also leading to apoptosis. Less frequent, non-apoptotic types of cell death have also been described following encounters with CTLs. The colour scale corresponds to the date of publication of discovery or use of the corresponding moiety. Note that most of the studies on the perforin-granzyme-mediated mechanism of cell death preceded those on the FAS-mediated pathway.
Serine esterases were likely candidates, as serine-esterase inhibitors blocked T cell-mediated cytotoxicity 82, 83 . Indeed serine esterases could be biochemically isolated from CTLs [84] [85] [86] [87] and moreover were localized in their granules [88] [89] [90] , hence being named granzymes.
Granzymes were independently identified through a subtractive cDNA cloning approach on the basis of the rationale that some of the molecules involved in cytotoxicity may be expressed only in cytotoxic cells. Such molecules with a restricted cellular distribution were identified by subtracting mRNAs from non-cytotoxic cells from CTL mRNAs and cloning the resulting material (reviewed in reF.
91
). This led to the identification of cytotoxic T lymphocyte antigen 3 (CTLA3) 92, 93 , which was identical to the independently identified Hanuka factor 94 and granzyme A, and of CTLA1 (reF.
92
), which was identical to the independently identified cytotoxic cell protease 1 (CCP1) 95 and granzyme B.
The role of granzymes in cytotoxicity was not easy to formally establish through gene inactivation because of functional redundancy. However, such a role was strongly suspected on the basis of, in particular, the apoptosis-like cytotoxicity that was observed in perforin-granzyme co-transfection experiments [96] [97] [98] . It later became clear that, usually with the help of perforin, effector cell granzymes can activate distinct death pathways within the target cell and can have multiple roles [99] [100] [101] [102] [103] .
The perforin-granzyme pathway does not fully account for cytotoxicity. Thus, by the late 1980s, a major granule exocytosis mechanism of CTL-mediated cytotoxicity was strongly suspected to involve both perforin and granzymes that were first localized within CTL granules and then somehow exocytosed to enter the target cell and cause its death by triggering apoptosis. However, in parallel, arguments were lining up to suggest that this mechanism did not fully account for cytotoxicity. For example, peritoneal exudate lymphocytes that seemed to lack both granules and substantial levels of perforin expression were highly cytotoxic 104 , which led researchers to discuss alternative explanations for cytotoxicity, including, in particular, cell surface death receptors 105 . Also, granule exocytosis and perforin-based cytotoxicity required Ca 2+ , but part of the cytotoxic activity of CTL populations or clones was found to be independent of extracellular Ca 2+ (reFs [106] [107] [108] [109] [110] ).
Scientific meetings discussing cytotoxicity were particularly lively at that time, with heated controversies between proponents of perforin-only, not-onlyperforin and no-perforin mechanisms. Even written comments on this debate had less-than-detached titles 111 .
Identifying the FAS pathway. If CTLs were indeed using two distinct mechanisms of cytotoxicity, then studying one of these mechanisms might benefit from excluding the other. One way to achieve this was to attempt to delete the known granule exocytosis mechanism from CTLs, for example, through loss of genetic material. The PC60 T cell hybridoma initially derived by Markus Nabholz, which was constitutive for growth and inducible for cytotoxicity upon addition of interleukins 112 , was a good starting point in this respect. PC60 is a heterospecific hybridoma between rat and mouse cells, and it was known that such hybridomas tend to randomly lose mouse or rat chromosomes. PC60 cells were grown in long-term culture and periodically cloned by limiting dilution (described in detail in reF.
113
). These clones were tested for their cytotoxicity against various target cells, with the clone showing highest levels of cytotoxicity being expanded, tested cytogenetically, grown again for several months, cloned again, and so on. This process was repeated for several years, leading to a tenth-generation PC60-d10S derivative. These d10S cells had lost approximately 20 chromosomes from the initial sum of the parental chromosomes. They showed non-MHC-restricted, Ca 2+ -independent cytotoxicity. When d10S cells were tested against a range of target cells, thymocytes were particularly sensitive to cytotoxicity 114 . While these results were being obtained, a striking report by Shigekazu Nagata and colleagues 115 mentioned that FAS, a known cell-death-transducing surface molecule 116, 117 , was abundantly expressed on thymocytes of wild-type mice but was not detectably expressed in lpr mice 115 . These results led to speculation that FAS could be involved in d10S-mediated cytotoxicity and offered a way to test this hypothesis. Indeed, whereas wild-type mouse thymocytes were sensitive to d10S-mediated cytotoxicity, lpr mouse thymocytes were not. Also, FAS-negative tumour target cells became sensitive to cytotoxic killing by d10S cells upon transfection of FAS 114 . This FAS-based mechanism of cytotoxicity was not limited to PC60-d10S cells, as the Ca 2+ -independent component 106,107 of antigen-specific cytotoxicity mediated by alloimmune peritoneal exudate cells lysed FAS-bearing, but not FAS-deficient, target cells 114 . In the summer of 1992, the report describing these results was rejected by Nature, rapidly accepted elsewhere and published in January 1993 (reF.
114
). These results showed that a mechanism of T cell-mediated cytotoxicity was FAS dependent.
Two pathways for cytotoxicity and identification of FASL. These results were further developed in two directions. First, in terms of cytotoxicity, it was shown that CTLs from perforin-knockout mice could still lyse target cells, which occurred through the FAS pathway, and that target cells from lpr mice could still be lysed by the perforin-granzyme pathway but, importantly, could not be lysed by perforin-knockout effector cells. These and other similar experiments showed that only two main mechanisms accounted for T cell-mediated cytotoxicity, namely, the perforin-granzyme-dependent granule exocytosis mechanism and the FAS-mediated mechanism [118] [119] [120] [121] . Second, at that time, several groups were trying to identify the ligand for FAS. It was reasoned that d10S cells, which exerted cytotoxicity through FAS expressed on target cells, must bear a ligand for FAS. The Nagata laboratory used a FASFc construct to further select d10S cell derivatives overexpressing the putative FAS ligand by fluorescence-activated cell sorting (FACS). They succeeded to clone the FAS ligand (FASL; also known as TNFSF6 and CD95L) from these cells by expression cloning and published the corresponding report in December 1993, within 1 year of receiving the d10S cells 122 . These and other early developments of FAS research were extensively reviewed at the time (for example, see reF. 123 ). Further studies showed that the perforin-granzyme pathway seems to be the dominant pathway for killing infected or transformed cells, whereas the FAS pathway seems to be more involved in regulating lymphocyte homeostasis 124 . Altogether, by the mid-1990s, the broad outlines of the FAS-based and the perforin-granzyme-based mechanisms by which CTLs can induce target cell death had been established. As a consequence, these years constituted a turning point for researchers in the field. Some turned to the study of cell death per se, whereas others went on studying, in greater molecular detail, the mechanisms of CTL-mediated cytotoxicity (Fig. 2) .
volume 18 | AuGuST 2018 | 531 Perforin-granzyme: 1990s In CD8 + T cells, the expression of perforin, granzymes and FASL was shown to be upregulated by, in particular, the transcription factors BLIMP1 (also known as PRDM1), eomesodermin and T cell-specific T-box transcription factor TBET through CD4 + T cell help in conjunction with changes in T cell metabolism (reviewed in reFs [125] [126] [127] [128] ). As revealed by immuno-electron microscopy in both NK cells and CTLs, perforin and granzymes colocalize with lysosomal hydrolases in a dual-function organelle that functions as both a lysosome and a secretory granule and is therefore known as a secretory lysosome 129, 130 . This raised the interesting question of how CTLs have evolved to turn a lysosome into a secretory organelle. A key finding emerged from genetic analysis of the primary immunodeficiency haemophagocytic lymphohistiocytosis (HLH), which is a rapidly fatal disease in which CTLs are unable to kill. Importantly, mutations in not only perforin 131 but also other molecules 132 led to HLH. The latter mutations were in genes encoding the proteins RAB27A, UNC13D (also known as MUNC13-4), syntaxin 11 and syntaxin-binding protein 2 (STXBP2; also known as MUNC18-2) 132 , which are required for secretion of the modified CTL lysosome.
An early indication of how CTL activation leads to granule secretion was provided by the observation of an increase in cytosolic Ca 2+ upon target cell recognition 133 . Following early observations in CTLs and NK cells of polarization of the Golgi apparatus and the microtubule-organizing centre towards target cells [134] [135] [136] , confocal imaging revealed the remarkable reorganization of receptors that occurs at the interface between T cells and antigen-presenting cells 137 . This led to the discovery of a specialized secretory domain within the corresponding immunological synapse of CTLs, where cytolytic granules deliver their cargo to target cells 138 . Further studies revealed a novel role for the centrosome in docking directly with the plasma membrane at the immunological synapse, thereby focusing secretion at the point of T cell receptor signalling 139 and ensuring that only the recognized target cells are killed. Ultimately, the granule contentsincluding perforin, granzymes and also the antimicrobial peptide granulysin (expressed in humans but not rodents) -ended up in the intercellular cleft between the CTL and target cell.
At the level of the target cell, perforin was required but not sufficient for lysis.
Perforin was shown to facilitate access of death-triggering granzymes to the cytosol by forming pores at the cell membrane 96, 140 . Several granzymes could induce apoptosis, but granzyme B seemed to be the most efficient and functioned by targeting caspases either directly or through the pro-apoptotic protein BH3-interacting domain death agonist (BID) 101 . Several granzymes could also lead to non-apoptotic forms of cell death 99 . Moreover, granzymes and granulysin could target and destroy intracellular parasites [141] [142] [143] [144] .
FAS: mid-1990s
One puzzle regarding FAS-based killing arose from the observation that FASL activity was rapidly inactivated by metalloproteinase cleavage of the extracellular domain at the plasma membrane 145 . Although this showed that FASL activity required membrane association and revealed a clear mechanism for downregulation of FAS-mediated killing, it also raised the question of how FASL might be active even transiently once at the plasma membrane. One possible answer is that FASL is packaged within cytotoxic granules in CTLs and NK cells 146 . Moreover, ubiquitylation signals in the cytosolic tail of FASL target it to intraluminal vesicles within such cytotoxic granules 147 , which is consistent with the observation of FASL activity within vesicle preparations 148 . Thus, FASL is found in intraluminal vesicles that surround the perforin-containing dense core within cytotoxic granules 149 . FASL-bearing vesicles would be released from cytotoxic granules upon secretion into the small cleft formed between the CTL and the FAS-bearing target cell to provide highly focused FASL-mediated killing.
In the target cell, as a FASL-constrained functional trimer 150 , FAS was shown to signal to FAS-associated death domain protein (FADD) 151 , leading to caspase 8 activation 152 and then caspase 3 activation and apoptosis. FAS-induced signalling was shown to be regulated in part by molecular recruitment to membrane rafts 153 and by post-translational modifications 154 . FAS signalling induced various other functions in addition to cell death [155] [156] [157] [158] . The lymphadenopathy that is prominent in mouse and human 159 mutants of the FAS pathway indicates that a main function of this pathway is to regulate the immune system, which classically occurs through the control of lymphocyte death, although other mechanisms have been proposed 158, 160 .
CTls and therapy
The knowledge that was accumulated over many years of research on T cell-mediated cytotoxicity started to lead to therapeutic applications, for example, through the molecular definition of the cytotoxicity mutants described above. In parallel, other developments were taking place that also turned out to be relevant to the role of CTLs in therapy. Perforin-deficient mice were shown to be more susceptible than wild-type mice to carcinogenesis, which implicated the immune system, and more precisely CTLs, in cancer immunosurveillance 161, 162 . Cancer immunotherapy was attempted using IL-2-activated lymphocytes 163 . In 1987, the immune checkpoint molecule CTLA4 was isolated through subtractive cDNA cloning 91, 164 , and about 5 years later, another checkpoint molecule, programmed cell death protein 1 (PD1), was similarly identified 165 . Ctla4-knockout mice 166, 167 and humans with CTLA4 mutations 168, 169 have similar lymphoproliferative phenotypes, which showed that CTLA4 has an inhibitory effect on lymphoid cells. Similarly, although not exactly the same, Pd1-knockout mice had splenomegaly, abnormalities of B cell proliferation and differentiation 170 and lupus-like autoimmune disease 171 , which suggested that PD1 maintains peripheral self-tolerance by negatively regulating immune responses 172 . The different phenotypes resulting from CTLA4 or PD1 deficiency or mutation reflect the fact that they function, at least in part, at distinct steps and also on distinct T cell subsets 173 . If CTLA4 and PD1 negatively regulate the activation of CTLs, contributing to their exhaustion 174 , then it was proposed that interfering with these molecules, using, for example, specific antibodies, could activate or reactivate CTLs to help eliminate or at least control tumour growth. Indeed, in tumour-bearing mice, antibodies directed against CTLA4 (reF.
175
).
or the PD1-programmed cell death 1 ligand 1 (PDL1) pathway 176, 177 could lead to tumour regression. Striking remissions were observed in a minority of patients with melanoma who were treated with antibodies against CTLA4 (reF.
178
) or PD1 (reFs 179, 180 ). Many clinical trials using such antibodies to treat other types of cancer are underway 181 . Although the possibility has not yet been fully explored, CTL activation using antibodies against such inhibitory checkpoint molecules may also have the potential to be used to fight viral, bacterial and parasitic infections 182, 183 . The alternative possibility arising from the discovery of checkpoint molecules was the ability to decrease CTL activity in certain therapeutic or pathological circumstances. Soluble CTLA4-Fc constructs can engage CD80 and CD86 (which are ligands of both CTLA4 and CD28) with high affinity, leading to inhibition of the CD28-mediated co-stimulation pathway and consequent inhibition of CTL activation 184, 185 . Such constructs were indeed shown to be efficient against some autoimmune diseases 186 and against graft rejection 187, 188 . A possible similar use of PD1 agonists is also being considered 189 . CTLs have also been effectively harnessed in other ways to control cancer. Instead of activating endogenous CTLs through the use of injected antibodies as described above, CTLs themselves can be injected into a patient 190 -in particular, after their transfection with genes encoding chimeric antigen receptors (CARs) 191, 192 . These CARs consist of an antibody-derived targeting fragment together with signalling domains that can activate T cells. Ideally, the antibody-derived fragment is selected to recognize, in an MHC-independent manner, an antigen that is present at the surface of cancer cells but not healthy cells. The signalling domains thus lead to activation of the CTLs, which then induce cancer cell death. Such CAR T cells have already shown striking efficacy at controlling some haematological malignancies 193 .
Conclusions
The past 60 years of research have led to the characterization of CTLs and mechanistic investigation of their cytotoxic effects. Perhaps the most thought-provoking result of these studies has been the realization that CTLs most often kill target cells by inducing signalling through the same apoptotic pathway that is used for developmental cell death. Within the past 30 years, further molecular investigations have led to existing or promising potential clinical applications for some genetic diseases, autoimmune and infectious diseases and graft rejection and perhaps most importantly for cancer immunotherapy using CTLs as a therapeutic tool. Research in the field of CTLs may now have reached the point where it has progressed beyond basic science and is dominated by medical applications, which will hopefully lead to further exciting therapeutic advances.
